Old age and multiple comorbidity are associated with delayed diagnosis of Guillain-Barre syndrome

Sohyeon Kim1, Hee Jo Han1, Ha Young Shin1

  • 1Department of Neurology, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea.

Scientific Reports
|June 15, 2022
PubMed

Insights

Older age and multiple comorbidities, including malignancy and cardiovascular diseases, are linked to delayed Guillain-Barré syndrome (GBS) diagnosis. Early GBS suspicion is crucial for these high-risk patients.

Area of Science:

  • Neurology
  • Clinical Medicine
  • Epidemiology

Background:

  • Guillain-Barré syndrome (GBS) diagnosis can be challenging.
  • Factors influencing diagnostic delay in GBS require further investigation.

Purpose of the Study:

  • To determine if older age and comorbidities are associated with delayed Guillain-Barré syndrome diagnosis.
  • To identify specific comorbidities that may prolong the time to GBS diagnosis.

Main Methods:

  • Retrospective review of 140 Guillain-Barré syndrome patient records (March 2011-December 2020).
  • Assessment of comorbidity profiles using the Charlson Comorbidity Index (CCI) and age-adjusted CCI (ACCI).
  • Classification of patients into early (≤14 days) and late (>14 days) diagnosis groups for comparative analysis.

Main Results:

  • Late diagnosis group showed significantly higher age (61.8 vs. 49.1 years) and CCI scores (26.1% vs. 5.1% with CCI ≥3).
  • Age-adjusted CCI score positively correlated with diagnosis duration (p < 0.001).
  • Diagnosis duration was significantly longer in patients with higher ACCI scores and specifically in those with malignancy and cardiovascular diseases.

Conclusions:

  • Delayed diagnosis of Guillain-Barré syndrome is associated with older age and a higher burden of comorbidities.
  • Malignancy and cardiovascular diseases are key comorbidities contributing to diagnostic delays in GBS.
  • Increased clinical suspicion for GBS is warranted in elderly patients and those with significant comorbidities, particularly cancer and heart disease.

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.3K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
32
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K